Estimating the Value of Adding 30 Days to the 180-Day Market Exclusivity of the First-to-File Generic Drug Manufacturer.

Pharmacoecon Open · 2026 · PMC12796020 · PMID 41004022

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the same model (Model 2(a)), in which PIV drugs have declining FTF generic sales, the regression shows a larger and highly significant 24.2% (SE: 0.067) decrease in sales for the FTF when an AG is present.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.